首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >TcM protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL)
【24h】

TcM protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL)

机译:TcM蛋白在B细胞慢性淋巴细胞性白血病(CLL)中起从头DNA甲基化的抑制剂的作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia. Deregulation of the T-cell teukemia/lymphoma 1 oncogene (TCL1) in mouse B cells causes a CD5~+ leukemia similar to aggressive human CLL. To examine the mechanisms by which TcM protein exerts its oncogenic activity in B cells, we performed proteomics experiments to identify its interacting partners. We found that Tel1 physically interacts with de novo DNA methylthansferases Dnmt3A and Dnmt3B. We further investigated the effects of TcM up-regulation on the enzymatic activity of Dnmt3A and found that Tcl1 overexpression drastically inhibits Dnmt3 A function. In addition, B cells from TCL1 transgenic mice showed a significant decrease in DNA methylation compared with WT controls. Similarly, CLL samples with high Tell expression showed a decrease in DNA methylation compared with CLL samples with low Tcl1 expression. Given the previous reports of inactivating mutations of DNMT3A in acute myelogenous leukemia and myelodysplastic syndrome, our results suggest that inhibition of de novo DNA methylation may be a common oncogenic mechanism in leukemogenesis.
机译:B细胞慢性淋巴细胞性白血病(CLL)是最常见的人类白血病。小鼠B细胞中T细胞白血病/淋巴瘤1癌基因(TCL1)的失控会导致CD5 +白血病,类似于侵略性人类CLL。为了检查TcM蛋白在B细胞中发挥其致癌活性的机制,我们进行了蛋白质组学实验以鉴定其相互作用的伴侣。我们发现Tel1物理上与从头DNA甲基转移酶Dnmt3A和Dnmt3B相互作用。我们进一步研究了TcM上调对Dnmt3A酶活性的影响,发现Tcl1的过表达极大地抑制了Dnmt3A的功能。此外,与野生型对照相比,TCL1转基因小鼠的B细胞DNA甲基化水平显着降低。同样,与低Tcl1表达的CLL样品相比,Tell表达高的CLL样品显示DNA甲基化减少。鉴于先前在急性骨髓性白血病和骨髓增生异常综合症中DNMT3A突变失活的报道,我们的结果表明,从头DNA甲基化的抑制可能是白血病发生中常见的致癌机制。

著录项

  • 来源
  • 作者单位

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Department of Medicine, University of California at San Diego, La Jolla, CA 92093;

    Department of Medicine, University of California at San Diego, La Jolla, CA 92093;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

    Human Cancer Genetics Program and Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University School of Medicine, Columbus, OH 43210;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号